Olema Stock Today


USD 2.49  0.30  10.75%   

Market Performance
0 of 100
Odds Of Distress
Less than 27
Olema Pharmaceuticals is trading at 2.49 as of the 7th of December 2022, a -10.75 percent decrease since the beginning of the trading day. The stock's open price was 2.79. Olema Pharmaceuticals has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Olema Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of December 2021 and ending today, the 7th of December 2022. Click here to learn more.
Fiscal Year End
IPO Date
19th of November 2020
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. The company has 40.46 M outstanding shares of which 1.63 M shares are now shorted by private and institutional investors with about 13.8 trading days to cover. More on Olema Pharmaceuticals

Moving together with Olema Pharmaceuticals

+0.67APGNApexigen Symbol ChangePairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Olema Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Olema Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Olema Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Olema Pharmaceuticals generated a negative expected return over the last 90 days
Olema Pharmaceuticals has high historical volatility and very poor performance
Net Loss for the year was (71.1 M) with profit before overhead, payroll, taxes, and interest of 0.
Olema Pharmaceuticals currently holds about 240.71 M in cash with (50.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 85.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Catalyst watch Eyes on Lululemon, GameStop, Disney and Exxon Mobil - Seeking Alpha
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Olema Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellFairly Valued
Olema Pharmaceuticals (OLMA) is traded on NASDAQ Exchange in USA and employs 73 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 100.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Olema Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Olema Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Olema Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 40.46 M outstanding shares of which 1.63 M shares are now shorted by private and institutional investors with about 13.8 trading days to cover. Olema Pharmaceuticals currently holds about 240.71 M in cash with (50.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Olema Pharmaceuticals Probability Of Bankruptcy
Olema Pharmaceuticals owns a total of fourty million four hundred fifty-five thousand four hundred outstanding shares. The majority of Olema Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Olema Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Olema Pharmaceuticals. Please pay attention to any change in the institutional holdings of Olema Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Olema Ownership Details

Olema Stock Price Odds Analysis

What are Olema Pharmaceuticals' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Olema Pharmaceuticals jumping above the current price in 90 days from now is more than 94.0%. The Olema Pharmaceuticals probability density function shows the probability of Olema Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3727. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Olema Pharmaceuticals will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Olema Pharmaceuticals is significantly underperforming NYSE Composite.
  Odds Below 2.49HorizonTargetOdds Above 2.49
6.10%90 days
Based on a normal probability distribution, the odds of Olema Pharmaceuticals to move above the current price in 90 days from now is more than 94.0 (This Olema Pharmaceuticals probability density function shows the probability of Olema Stock to fall within a particular range of prices over 90 days) .

Olema Pharmaceuticals Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Olema Pharmaceuticals market risk premium is the additional return an investor will receive from holding Olema Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Olema Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Olema Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Olema Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.

Olema Stock Against Markets

Picking the right benchmark for Olema Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Olema Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Olema Pharmaceuticals is critical whether you are bullish or bearish towards Olema Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Olema Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now


Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Olema Pharmaceuticals Corporate Management

Elected by the shareholders, the Olema Pharmaceuticals' board of directors comprises two types of representatives: Olema Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Olema. The board's role is to monitor Olema Pharmaceuticals' management team and ensure that shareholders' interests are well served. Olema Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Olema Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Cyrus Harmon - Chief DirectorProfile
Courtney Dugan - VP CommunicationsProfile
John Moriarty - Chief VPProfile
Shane MBA - Chief OfficerProfile
Julie Dexter - VP PeopleProfile
Peter Kushner - CoFounder FellowProfile
PharmD Faltaos - VP PharmacologyProfile

Invested in Olema Pharmaceuticals?

The danger of trading Olema Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Olema Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Olema Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Olema Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Your Equity Center. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for analysis

When running Olema Pharmaceuticals price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Olema Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
100.7 M
Return On Assets
Return On Equity
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Olema Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.